pd168393 has been researched along with Adenocarcinoma in 1 studies
PD 168393 : A member of the class of quinazolines carrying bromoanilino and acrylamido substituents at positions 4 and 6 respectively.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pu, YS | 1 |
| Hsieh, MW | 1 |
| Wang, CW | 1 |
| Liu, GY | 1 |
| Huang, CY | 1 |
| Lin, CC | 1 |
| Guan, JY | 1 |
| Lin, SR | 1 |
| Hour, TC | 1 |
1 other study available for pd168393 and Adenocarcinoma
| Article | Year |
|---|---|
Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.
Topics: Adenocarcinoma; Androgens; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Combinations | 2006 |